Insider Selling: IDEXX Laboratories, Inc. (NASDAQ:IDXX) VP Sells 8,598 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) VP Jacqueline Studer sold 8,598 shares of the stock in a transaction on Monday, August 6th. The shares were sold at an average price of $242.37, for a total value of $2,083,897.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jacqueline Studer also recently made the following trade(s):

  • On Tuesday, August 21st, Jacqueline Studer sold 11,619 shares of IDEXX Laboratories stock. The shares were sold at an average price of $244.03, for a total value of $2,835,384.57.
  • On Wednesday, May 30th, Jacqueline Studer sold 475 shares of IDEXX Laboratories stock. The shares were sold at an average price of $209.98, for a total value of $99,740.50.

NASDAQ:IDXX traded up $0.56 on Friday, hitting $254.04. The stock had a trading volume of 372,000 shares, compared to its average volume of 488,430. The stock has a market capitalization of $21.79 billion, a price-to-earnings ratio of 77.12, a PEG ratio of 2.30 and a beta of 0.69. The company has a debt-to-equity ratio of -14.77, a quick ratio of 0.73 and a current ratio of 0.96. IDEXX Laboratories, Inc. has a 52-week low of $146.09 and a 52-week high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, August 1st. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.06. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The business had revenue of $580.75 million for the quarter, compared to analysts’ expectations of $574.68 million. During the same period last year, the firm posted $0.87 earnings per share. The business’s revenue for the quarter was up 14.1% on a year-over-year basis. equities analysts forecast that IDEXX Laboratories, Inc. will post 4.18 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of IDXX. Signaturefd LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth about $105,000. Three Peaks Capital Management LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth about $108,000. Valeo Financial Advisors LLC bought a new position in shares of IDEXX Laboratories in the second quarter worth about $134,000. Optimum Investment Advisors bought a new position in shares of IDEXX Laboratories in the first quarter worth about $139,000. Finally, Cerebellum GP LLC bought a new position in shares of IDEXX Laboratories in the second quarter worth about $181,000. 91.19% of the stock is currently owned by hedge funds and other institutional investors.

IDXX has been the topic of several recent analyst reports. Stifel Nicolaus increased their price objective on IDEXX Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, May 7th. Credit Suisse Group raised their target price on IDEXX Laboratories from $209.00 to $228.00 and gave the stock an “outperform” rating in a research report on Friday, June 1st. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 9th. BidaskClub cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 9th. Finally, Canaccord Genuity reissued a “positive” rating and issued a $215.00 target price on shares of IDEXX Laboratories in a research report on Monday, May 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $244.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: Leveraged Buyout (LBO)

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply